Hector Samaniego
Child & Adolescent Psychiatry · San Antonio, TXNPI 1487651527
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,357 and has fallen 97.4% since, to $36 in 2025.
Across 126 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$461
- Otsuka America Pharmaceutical, Inc.$397
- AbbVie$383
- Johnson & Johnson$161
- Vertical Pharmaceuticals, LLC$140
- Shire North American Group Inc$80
- plus $354 from 10 others
What the payments were for
- Food & beverage$1,92898%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
How this compares
$1,975 in reported general payments places this provider in the 80th percentile of 301 child & adolescent psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $49,933 |
| Abilify MaintenaAripiprazole | 18 | $49,273 |
| Lurasidone Hcl | 95 | $19,854 |
| VraylarCariprazine Hcl | 14 | $18,991 |
| Oxcarbazepine | 24 | $9,220 |
| Fluphenazine Hcl | 30 | $3,765 |
| Ziprasidone Hcl | 22 | $2,373 |
| Olanzapine OdtOlanzapine | 11 | $1,202 |
| Perphenazine | 11 | $1,096 |
| Alprazolam | 92 | $786 |
| Vilazodone Hcl | 12 | $769 |
| Sertraline Hcl | 11 | $477 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $450 |
| Fluoxetine Hcl | 70 | $408 |
| Quetiapine Fumarate | 21 | $325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $35 | $49,93311 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $397 | $49,27318 claims |
| AbbVieVraylar | $383 | $18,99114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 301 child & adolescent psychiatry providers in Texas.
Other child & adolescent psychiatry in San Antonio
- Steven PliszkaSan Antonio$59K
- Mary Garcia HolguinSan Antonio$24K
- Maria DominguezSan Antonio$7K
- Amber MansoorSan Antonio$6K
- Andrew MartinSan Antonio$6K
- Thomas DemoorSan Antonio$5K
- Vanessa VelaSan Antonio$3K
- Marguerite HoganSan Antonio$3K
- Grace Salinas GarciaSan Antonio$2K
- Alain KaticBellaire$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.